New Serological Pipettor Improves Liquid Handling Productivity
Building upon over 30 years of unmatched quality and hundreds of thousands of instruments in use worldwide, INTEGRA has launched the new PIPETBOY acu 2 serological pipettor.
The second generation of PIPETBOY acu is equipped with the latest technology providing a significant increase in pipetting speed and a sizeable weight reduction making using the instrument over extended periods of time even more comfortable. These two new developments help improve productivity and deliver an enhanced ergonomic pipetting experience.
Liquid handling in the millilitre range using serological pipettes is a daily task for many labs. Unlike rubber bulb fillers, the use of seriological pipettors improves the efficiency and precision of your liquid handling. The PIPETBOY acu 2 serological pipettor combines all essential characteristics for productive work with pipettes: precision, speed, ease-of-use, comfort, long operating battery life and reliability. PIPETBOY acu 2 is designed for use with all commercially available glass and plastic serological pipettes in the 1–100 mL volume range.
Pipetting using PIPETBOY acu 2 is controlled by two operating buttons and an adjustment wheel for setting the pipetting speed. Precise drop-by-drop dispensing is easily achieved by applying a slight pressure on the operating button. When working with large volume pipettes, the new Turbo Mode provides the instrument with 20% extra pipetting speed, making it the fastest pipettor on the market. Powered by a new high-performance Lithium Polymer battery, PIPETBOY acu 2 now provides an extended operating time of more than 6.5 hours non-stop pipetting. To avoid contamination from accidentally absorbed liquids PIPETBOY acu 2 is protected by a hydrophobic filter. PIPETBOY acu 2 is available in a range of six attractive colours.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance